TICKERNOMICS Sign up
Last Update: 2024-03-28 02:10:34
Krystal Biotech Inc. ( KRYS ) https://www.krystalbio.com
174.17USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
KRYS
119.97%
SPY
32.74%
KRYS
152.64%
SPY
92.93%
KRYS
429.39%
SPY
224.41%
KRYS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4723.71
4542.98
0.26
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-158.45
441.14
6.07
-2.07
0.00
-41.41
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-303.80
100.00
-320.58
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.2309
-20.60
-15.81
1.33
Other Earnings and Cash Flow Stats:
Krystal Biotech Inc. ( KRYS ) Net Income TTM ($MM) is -26.45
Krystal Biotech Inc. ( KRYS ) Operating Income TTM ($MM) is -141.04
Krystal Biotech Inc. ( KRYS ) Owners' Earnings Annual ($MM) is 30.89
Krystal Biotech Inc. ( KRYS ) Current Price to Owners' Earnings ratio is 159.19
Krystal Biotech Inc. ( KRYS ) EBITDA TTM ($MM) is -85.85
Krystal Biotech Inc. ( KRYS ) EBITDA Margin is -320.58%
Capital Allocation:
Krystal Biotech Inc. ( KRYS ) has paid 0.00 dividends per share and bought back -2.744952 million shares in the past 12 months
Krystal Biotech Inc. ( KRYS ) has reduced its debt by 0.839 million USD in the last 12 months
Capital Structure:
Krystal Biotech Inc. ( KRYS ) Interest-bearing Debt ($MM) as of last quarter is 8
Krystal Biotech Inc. ( KRYS ) Annual Working Capital Investments ($MM) are 49
Krystal Biotech Inc. ( KRYS ) Book Value ($MM) as of last quarter is 778
Krystal Biotech Inc. ( KRYS ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Krystal Biotech Inc. ( KRYS ) has 358 million in cash on hand as of last quarter
Krystal Biotech Inc. ( KRYS ) has 33 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Krystal Biotech Inc. ( KRYS ) has 28 common shares outstanding as of last quarter
Krystal Biotech Inc. ( KRYS ) has 0 million USD of preferred stock value
Academic Scores:
Krystal Biotech Inc. ( KRYS ) Altman Z-Score is 71.20 as of last quarter
Krystal Biotech Inc. ( KRYS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Krystal Biotech Inc. ( KRYS ) largest shareholder is Credit Suisse First Boston (CSFB) owning 233621 shares at 40.69 ($MM) value
Suma Krishnan(an insider) Sold 25000 shares of Krystal Biotech Inc. ( KRYS ) for the amount of $4274000.00 on 2024-03-11
13.96% of Krystal Biotech Inc. ( KRYS ) is held by insiders, and 80.55% is held by institutions
Krystal Biotech Inc. ( KRYS ) went public on 2017-09-20
Other Krystal Biotech Inc. ( KRYS ) financial metrics:
FCF:-93.28
Unlevered Free Cash Flow:-119.42
EPS:11.44
Operating Margin:-303.80
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:41.48
Beta:1.33
Buffet's Owners Earnings:30.89
Price to Owner's Earnings:159.19
About Krystal Biotech Inc. ( KRYS ) :
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.